| Immunotherapy for colorectal cancer: where are we heading? D Basile, SK Garattini, M Bonotto, E Ongaro, M Casagrande, M Cattaneo, ... Expert opinion on biological therapy 17 (6), 709-721, 2017 | 105 | 2017 |
| Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue V Longo, O Brunetti, A Gnoni, S Cascinu, G Gasparini, V Lorusso, ... Oncotarget 7 (36), 58649, 2016 | 98 | 2016 |
| Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale AC Gardini, L Faloppi, S De Matteis, FG Foschi, N Silvestris, F Tovoli, ... European Journal of Cancer 86, 106-114, 2017 | 94 | 2017 |
| Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials O Kooshkaki, A Derakhshani, N Hosseinkhani, M Torabi, S Safaei, ... International journal of molecular sciences 21 (12), 4427, 2020 | 82 | 2020 |
| CAFs and TGF-β signaling activation by mast cells contribute to resistance to gemcitabine/nabpaclitaxel in pancreatic cancer L Porcelli, RM Iacobazzi, R Di Fonte, S Serratì, A Intini, AG Solimando, ... Cancers 11 (3), 330, 2019 | 81 | 2019 |
| Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance K Danza, N Silvestris, G Simone, M Signorile, L Saragoni, O Brunetti, ... Cancer biology & therapy 17 (4), 400-406, 2016 | 80 | 2016 |
| Gene expression comparison between the lymph node-positive and-negative reveals a peculiar immune microenvironment signature and a theranostic role for WNT targeting in … A Argentiero, S De Summa, R Di Fonte, RM Iacobazzi, L Porcelli, ... Cancers 11 (7), 942, 2019 | 79 | 2019 |
| MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? O Brunetti, A Russo, A Scarpa, D Santini, M Reni, A Bittoni, A Azzariti, ... Oncotarget 6 (27), 23323, 2015 | 78 | 2015 |
| Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies? N Hosseinkhani, A Derakhshani, O Kooshkaki, M Abdoli Shadbad, ... International Journal of Molecular Sciences 21 (21), 8305, 2020 | 77 | 2020 |
| Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib A Casadei Gardini, G Marisi, E Scarpi, M Scartozzi, L Faloppi, N Silvestris, ... Expert opinion on pharmacotherapy 16 (18), 2719-2725, 2015 | 74 | 2015 |
| Predictive and prognostic factors in HCC patients treated with sorafenib O Brunetti, A Gnoni, A Licchetta, V Longo, A Calabrese, A Argentiero, ... Medicina 55 (10), 707, 2019 | 72 | 2019 |
| Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? A Gnoni, D Santini, M Scartozzi, A Russo, A Licchetta, V Palmieri, L Lupo, ... Expert opinion on therapeutic targets 19 (12), 1623-1635, 2015 | 70 | 2015 |
| Pancreatic enzyme replacement therapy in pancreatic cancer R Pezzilli, R Caccialanza, G Capurso, O Brunetti, M Milella, M Falconi Cancers 12 (2), 275, 2020 | 68 | 2020 |
| Cytotoxic T-lymphocyte antigen-4 in colorectal cancer: another therapeutic side of capecitabine A Derakhshani, S Hashemzadeh, Z Asadzadeh, MA Shadbad, ... Cancers 13 (10), 2414, 2021 | 66 | 2021 |
| Targeting angiogenesis in biliary tract cancers: an open option V Simone, O Brunetti, L Lupo, M Testini, E Maiorano, M Simone, V Longo, ... International journal of molecular sciences 18 (2), 418, 2017 | 65 | 2017 |
| Role of BRAF in hepatocellular carcinoma: a rationale for future targeted cancer therapies A Gnoni, A Licchetta, R Memeo, A Argentiero, AG Solimando, V Longo, ... Medicina 55 (12), 754, 2019 | 64 | 2019 |
| Immunotherapeutic approaches for hepatocellular carcinoma V Longo, A Gnoni, AC Gardini, S Pisconti, A Licchetta, M Scartozzi, ... Oncotarget 8 (20), 33897, 2017 | 64 | 2017 |
| Anti-angiogenesis and immunotherapy: novel paradigms to envision tailored approaches in renal cell-carcinoma A Argentiero, AG Solimando, M Krebs, P Leone, N Susca, O Brunetti, ... Journal of Clinical Medicine 9 (5), 1594, 2020 | 57 | 2020 |
| Immune system and bone microenvironment: Rationale for targeted cancer therapies A Gnoni, O Brunetti, V Longo, A Calabrese, R Calbi, GS Antonio, ... Oncotarget 11 (4), 480, 2020 | 54 | 2020 |
| In vitro anti‐myeloma activity of TRAIL‐expressing adipose‐derived mesenchymal stem cells S Ciavarella, G Grisendi, M Dominici, M Tucci, O Brunetti, F Dammacco, ... British journal of haematology 157 (5), 586-598, 2012 | 53 | 2012 |
prof. Nicola Silvestris - Full Professor i...Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, ItalyBestätigte E-Mail-Adresse bei unime.it
